TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03860584

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MFGM-enriched full-fat dairy milk
Description: MetS adults with metabolic endotoxemia will be enrolled to complete a 2-arm, double-blind, randomized controlled, crossover trial to test the independent benefits of MFGM. For each 2-wk arm, they will receive MFGM-enriched full-fat dairy milk (3 servings/d) or a matched dairy milk that instead contains soy phospholipid/lecithin (control). Milks have been formulated with soy lecithin or MFGM at 10% phospholipid (relative to total lipid content). This delivers MFGM at \~10-times that in full-fat dairy milk, which reflects that consumers obtain MFGM from dairy foods other than whole milk.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Soy phospholipid/lecithin milk
Description: MetS adults with metabolic endotoxemia will be enrolled to complete a 2-arm, double-blind, randomized controlled, crossover trial to test the independent benefits of MFGM. For each 2-wk arm, they will receive MFGM-enriched full-fat dairy milk (3 servings/d) or a matched dairy milk that instead contains soy phospholipid/lecithin (control). Milks have been formulated with soy lecithin or MFGM at 10% phospholipid (relative to total lipid content).
Study: NCT02099266

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Administration of hyperbaric oxygen
Description: Hyperbaric oxygen at 2.5 atmospheres absolute (ATA) for a total of 2 hours
Study: NCT01561183

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Indirect pulp capping (IPC)
Description: Procedure: IPC~The IPC will be performed as follow:~* Anesthesia~* isolation the tooth~* access to the lesion~* incomplete removal of carious tissue from the cavity walls~* indirect pulp capping with ≈2 mm layer calcium enriched mixture cement~* permanent filling with sandwich technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct pulp capping (DPC)
Description: Procedure: DPC~The DPC will be performed as follow:~* Anesthesia~* isolation the tooth~* access to the lesion~* complete removal of carious tissue from the cavity walls result in pulp exposure~* preparation of clot-free pulpal mound~* direct pulp capping with ≈2 mm layer calcium enriched mixture cement~* permanent filling with sandwich technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Miniature pulpotomy (MP)
Description: Procedure: MP~The MP will be performed as follow:~* Anesthesia~* isolation the tooth~* access to the lesion~* complete removal of carious tissue from the cavity walls result in pulp exposure~* intentionally removal of pulp horn (≈1 mm)~* preparation of clot-free pulpal mound~* direct pulp capping with ≈2 mm layer calcium enriched mixture cement~* permanent filling with sandwich technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full pulpotomy (FP)
Description: Procedure: FP~The FP will be performed as follow:~* Anesthesia~* isolation the tooth~* access to the lesion~* complete removal of carious tissue from the cavity walls result in pulp exposure~* pulpotomy~* preparation of clot-free pulpal mound~* direct pulp capping with ≈2 mm layer calcium enriched mixture cement~* permanent filling with sandwich technique
Study: NCT03799887

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 0% unweighed BWSTT
Description: 30 minutes conventional rehabilitation program (CRP) including range of motion, stretching and strengthening exercises for upper and lower extremities, balance and mobility exercises.~After CRP, participants were provided 30 minutes 0% unweighed BWSTT sessions including a 5 minutes warm - up and cool - down period for each session, 5 days a week, for 6 weeks (totally, 30 sessions).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10% unweighed BWSTT
Description: 30 minutes conventional rehabilitation program (CRP) including range of motion, stretching and strengthening exercises for upper and lower extremities, balance and mobility exercises.~After CRP, participants were provided 30 minutes 10% unweighed BWSTT sessions including a 5 minutes warm - up and cool - down period for each session, 5 days a week, for 6 weeks (totally, 30 sessions).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 20% unweighed BWSTT
Description: 30 minutes conventional rehabilitation program (CRP) including range of motion, stretching and strengthening exercises for upper and lower extremities, balance and mobility exercises.~After CRP, participants were provided 30 minutes 20% unweighed BWSTT sessions including a 5 minutes warm - up and cool - down period for each session, 5 days a week, for 6 weeks (totally, 30 sessions).
Study: NCT00673985

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Transluminal Angioplasty
Description: Balloon Angioplasty

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LifeStent NT™ Self-Expanding Peripheral Stent
Description: Balloon angioplasty plus stent
Study: NCT02454270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1 (Dose Escalation): Duvortuxizumab
Description: Participants currently enrolled in the study will continue to receive duvortuxizumab every 14 days (biweekly dosing) in each 28 -day cycle as an intravenous infusion. In the priming dose regimen, a priming dose will be administered on Day 1 followed by full doses on Day 8 and Day 22, of a 35-day Cycle 1, and then every 14 days in each subsequent 28-day cycle. The cohorts will be opened where participants will receive duvortuxizumab every 7 days (for investigating weekly dosing schedule) in each 28-day cycle as an intravenous infusion. In the priming dose regimen, a priming dose will be administered on Day 1 followed by full doses on Day 8, Day 15, Day 22, and Day 28 of a 35-day Cycle 1, and then every 7 days in each subsequent 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2 (Dose Expansion): Duvortuxizumab
Description: Participants will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) defined in Part 1 for their disease type either with or without a priming dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2 (Dose Expansion): Duvortuxizumab
Description: Participants will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) defined in Part 1 for their disease type either with or without a priming dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2 (Dose Expansion): Duvortuxizumab
Description: Participants will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) defined in Part 1 for their disease type either with or without a priming dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2 (Dose Expansion): Duvortuxizumab
Description: Participants will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) defined in Part 1 for their disease type either with or without a priming dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2 (Dose Expansion): Duvortuxizumab
Description: Participants will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) defined in Part 1 for their disease type either with or without a priming dose.
Study: NCT01930084

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Point of care CD4+ after HIV diagnosis
Description: Point of care (POC) CD4+ testing immediately following HIV diagnosis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Point of care CD4+ after HIV diagnosis
Description: Point of care (POC) CD4+ testing immediately following HIV diagnosis
Study: NCT01699269

Intervention type: OTHER
Group type: OTHER
Intervention: peritumoral glial cell infiltration
Study: NCT00806663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib added to FOLFIRI
Description: sunitinib 37 mg once daily (4 weeks on/2 weeks off)
Study: NCT02964208

Intervention type: DEVICE
Intervention: AMPLATZER™ LAA Occluder
Description: The AMPLATZER™ LAA Occluder is intended to prevent thrombus embolization from the left atrial appendage (LAA) in patients who have nonvalvular Atrial Fibrillation (AF). It may be considered for use in patients who have a high risk of stroke and bleeding and are deemed by their physician to have an appropriate rationale to seek a non-pharmacologic alternative to long term anticoagulants.
Study: NCT04073004

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rapid Resolution Therapy
Description: psychotherapy that includes trance states
Study: NCT02430246

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Urex Plus
Description: Probiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Urex Plus
Description: Probiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Urex Plus
Description: Probiotic

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule without active ingredient

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule without active ingredient

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule without active ingredient

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Probotic capsule containing L. rhamnosus GR-1and L. reuteri RC-14

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Probotic capsule containing L. rhamnosus GR-1and L. reuteri RC-14
Study: NCT03189693

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PVB
Description: nerve stimulator-guided PVB will be performed at two levels

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: nerve stimulator-guided PVB containing placebo will be performed at two levels

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GA
Description: All patients will receive general anesthesia.
Study: NCT06733506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Description: Chlorhexidine gluconate (CHG) is a cationic bisguanide that works through disruption of cell membranes. CHG has broad spectrum activity against gram-positive bacteria and to a lesser extent gram negative bacteria. CHG has significant residual activity and addition of alcohol based preparations results in even greater residual activity compared to alcohol alone. CHG acts in the presence of organic material (e.g., blood and biofilm) and its antimicrobial activity is slower than that of alcohols.~Prevantics® 1 ml Swab contains a cutaneous solution of 3.15% w/v chlorhexidine gluconate (CHG) and 70% v/v isopropyl alcohol (IPA), which is commonly used for the preparation of a patient's skin prior to surgery or venipuncture. Prevantics® Swab is available as a single use pre-moistened 2-sided applicator (1.0 ml).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isopropyl Alcohol 70% Topical Application Solution
Description: Isopropyl alcohol (IPA), a topical skin disinfectant, is effective against many pathogens and is commonly supplied as 2x2 inch pre-soaked, single-use gauze wipes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skin Prep Before Injecting Recreational/Street Drugs
Description: During a single 10 minute session, a healthcare provider gives the participant verbal and written information, counseling, and training to reinforce participant knowledge, motivation, and skills to practice skin swabbing correctly and routinely before injecting.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Skin Prep Before Injecting Recreational/Street Drugs
Description: During a single 10 minute session, a healthcare provider gives the participant verbal and written information, counseling, and training to reinforce participant knowledge, motivation, and skills to practice skin swabbing correctly and routinely before injecting.
Study: NCT06732635

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enhanced recovery after surgery (ERAS)
Description: Enhanced recovery after surgery (ERAS) programs are designed to achieve early recovery after surgery and a shorter length of stay (LOS) at hospital.
Study: NCT01620866

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization Reprocessing (EMDR)
Description: EMDR is an effective treatment in PTSD but has never been tested in bipolar traumatized patients.
Study: NCT01385345

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3 cholecalciferol
Description: High dose Vitamin D3 (200,000 units followed by 100,000 units x 3 over 6 months) plus daily 1,000 units Vitamin D3 per day vs only daily 1,000 units Vitamin D3 per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 cholecalciferol
Description: High dose Vitamin D3 (200,000 units followed by 100,000 units x 3 over 6 months) plus daily 1,000 units Vitamin D3 per day vs only daily 1,000 units Vitamin D3 per day
Study: NCT01436825

Intervention type: DRUG
Intervention: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Description: Prophylactic treatment : 20-40 UI /Kg administered all 2 in 3 days .
Study: NCT02803775

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRT Algorithm
Description: Programming based on Electrogram measurement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRT Algorithm
Description: Programming based on Electrogram measurement
Study: NCT01489579

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Counseling for Tobacco Cessation
Description: The patients in the Brief, Structured, Telephone (BST) counseling group will receive tobacco cessation counseling by a trained CPCRS pharmacist as part of their routine CPCRS care. The counseling will not be scripted, but must contain three key components (recommendation to quit, discussion/recommendation of tobacco cessation medications, and discussion/recommendation of tobacco cessation methods/strategies (Appendix C). These are the same items measured by the National Committee for Quality Assurance (NCQA) for Healthcare Effectiveness and Data Information Set (HEDIS) reporting. A standard KPCO document will be mailed to the patients following the BST counseling containing information about available resources (Ready to quit patient handout)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Pharmacists randomized to Usual Care will continue to provide interventions/procedures they normally would according to usual care practices. These interventions include any of the following: no action, mailed information on the resources available to help aid tobacco cessation, telephone counseling, and/or assistance in getting tobacco cessation medications. Pharmacists who are randomized to Usual Care will be asked to continue their current approach for tobacco cessation recommendations
Study: NCT04462861

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Central venous access device (CVAD) Snuggie Securement Device
Description: Participants will be given a prototype of a CVAD securement device for a three week trial. Descriptive data relating to user satisfaction will be collected at 1 and 3 weeks
Study: NCT02681913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine
Description: This group receives intermittent warm blood cardioplegia enriched with adenosine
Study: NCT05090709

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal Mobilisation Intervention
Description: 30 minutes spinal mobilisations, rate = 0.37Hz, 22 beats per minute, force = less than grade 1, threshold of 80N, location = L1-L5.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General Massage
Description: 30 minutes manual touch with no specifications or recordings on rate, pressure or location of touch.
Study: NCT04811430

Intervention type: DEVICE
Intervention: Randomized Traditional
Description: Traditional ultrasound guidance was utilized to insert Midlines on simulated veins blocks not live patients

Intervention type: DEVICE
Intervention: Randomized Traditional
Description: Traditional ultrasound guidance was utilized to insert Midlines on simulated veins blocks not live patients

Intervention type: DEVICE
Intervention: Cue(TM) Needle Tracking Technology
Description: Cue(TM) Needle Tracking Technology with real time needle tip tracking is used to assist ultrasound guided midline insertions on simulated veins blocks not live patients

Intervention type: DEVICE
Intervention: Cue(TM) Needle Tracking Technology
Description: Cue(TM) Needle Tracking Technology with real time needle tip tracking is used to assist ultrasound guided midline insertions on simulated veins blocks not live patients
Study: NCT04010071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axitinib plus toripalimab
Description: Axitinib 5mg, twice a day, orally, 4 weeks a cycle. Dose reduction from 5mg twice a day to 3mg twice a day should be considered according to adverse events.~Toripalimab 240mg, every 3 weeks, intravenous infused, 6 weeks a cycle. Number of cycle: until disease progression or unacceptable toxicity events.
Study: NCT02676102

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Generic Video about organ donation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Targeted Intervention
Description: an educational video produced in partnership with the community of black men including customers, employees, and owners of BOBs. Video production was informed by entertainment education models and produced with experts including an Academy Award winning filmmaker.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tailored Intervention
Description: Videos with content individualized to participant's pre-intervention Organ Donation Belief Index (ODBI).
Study: NCT03702842

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soterix Medical tsDCS stimulator
Description: tsDCS will be delivered to the lumbar region of the spinal cord with electrodes placed over the low back and abdomen. The electrodes will be secured with a large elastic bandage so that stimulation can be applied for up to 30 minutes during locomotor training with a harness attached to the ceiling for safety. A physical therapist will supervise the session.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soterix Medical tsDCS stimulator
Description: tsDCS will be delivered to the lumbar region of the spinal cord with electrodes placed over the low back and abdomen. The electrodes will be secured with a large elastic bandage so that stimulation can be applied for up to 30 minutes during locomotor training with a harness attached to the ceiling for safety. A physical therapist will supervise the session.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Soterix Medical tsDCS stimulator
Description: tsDCS will be delivered to the lumbar region of the spinal cord with electrodes placed over the low back and abdomen. The electrodes will be secured with a large elastic bandage so that stimulation can be applied for up to 30 minutes during locomotor training with a harness attached to the ceiling for safety. A physical therapist will supervise the session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Locomotor training
Description: Participants will complete 16 sessions of locomotor training (4 times per week for 4 weeks). This involves walking on a treadmill for up to 30 minutes with a harness attached to the ceiling for safety, followed by 10 minutes of overground walking training; with physical assistance as needed.
Study: NCT03189693

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: GA
Description: All patients will receive general anesthesia.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anesthetic injections
Description: 4 mL of the local anesthetic mixture is injected at each injection site. Each 20 mL of the local anaesthetic mixture contains: 8mL lidocaine 2%, 8 mL lidocaine 2% with epinephrine 5µg/mL and 4 mL bupivacaine 0.5%.
Study: NCT03702842

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Locomotor training
Description: Participants will complete 16 sessions of locomotor training (4 times per week for 4 weeks). This involves walking on a treadmill for up to 30 minutes with a harness attached to the ceiling for safety, followed by 10 minutes of overground walking training; with physical assistance as needed.
Study: NCT00976599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550 + methotrexate
Description: CP-690,550 dose is 10 mg twice daily, oral tablets, for 4 weeks Methotrexate dose is ≥ 7.5 mg / week and ≤ 25 mg / week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Methotrexate
Description: Methotrexate dose is ≥ 7.5 mg / week and ≤ 25 mg / week
Study: NCT04239040

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue collection
Description: Collection of cancerous tissue to create GVAX vaccine or irradiated GMCSF-secreting autologous neuroblastoma cell vaccine at time of clinically indicated surgical procedure

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVAX vaccine
Description: Vaccine injected weekly over initial 21 day cycle, biweekly for cycles 2-4 of 21 day cycle duration and cycles 5 and subsequent of 28 day cycle duration until vaccine supply is exhausted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Intravenous infusion of nivolumab every 3 weeks, for cycles 1-4. Cycles 1-4 are 21 days~Intravenous infusion of nivolumab biweekly for cycle 5 and subsequent of 28 day cycle duration. Subsequent 28 day cycles will last up to 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Intravenous infusion of ipilimumab every 3 weeks, for cycles 1-4. Cycles 1-4 are 21 days
Study: NCT03984799

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: Samples obtained during bronchoscopy and blood samples will be evaluated to define inflammatory markers of COPD
Study: NCT02468401

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Description: Patients planned for coronary angiography or percutaneous coronary intervention will be managed using a protocol that allows us to use minimal volumes of contrast dye
Study: NCT02904408

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychotherapy
Description: Group psychotherapy